Data Sheet 1_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.pdf

Data Sheet 1_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.pdf

Introduction<p>Fibrates are effective triglyceride-lowering drugs, but they may affect bile acid metabolism, raising concerns about biliary adverse drug events (ADEs).</p>Objective<p>In this study, we used spontaneous reporting system databases to evaluate the association between f...

Saved in:

書目詳細資料
主要作者:	Satoko Watanabe (59124) (author)
其他作者:	Kyosuke Nagura (22675574) (author), Naoto Okada (7836800) (author), Taro Watanabe (15278960) (author), Hidenori Sagara (22675577) (author)
出版:	2025
主題:	Pharmacology fibrates pemafibrate biliary adverse events pharmacovigilance disproportionality analysis time-to-onset analysis JADER FAERS
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Table 3_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx
由: Satoko Watanabe (59124)
出版: (2025)

Table 2_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx
由: Satoko Watanabe (59124)
出版: (2025)

Table 4_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx
由: Satoko Watanabe (59124)
出版: (2025)

Table 1_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx
由: Satoko Watanabe (59124)
出版: (2025)

Table 2_A pharmacovigilance study of Bruton’s tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase.xlsx
由: Han Qu (4391905)
出版: (2025)

Table 1_A pharmacovigilance study of Bruton’s tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase.docx
由: Han Qu (4391905)
出版: (2025)

Two-by-two contingency table for disproportionality analysis.
由: Jun Hua Lai (22676523)
出版: (2025)

Impact of sodium glucose cotransporter 2 inhibitors on bladder cancer and breast cancer: a pharmacovigilance analysis and mendelian randomization study
由: Bo Xu (233514)
出版: (2025)

Association of a COVID-19 diagnosis with adverse events, cohort design, follow-up starting on the day after time 0.
由: Shelby S. Fisher (22676406)
出版: (2025)

Enhancing dose selection in phase I cancer trials: Extending the Bayesian Logistic Regression Model with non-DLT adverse events integration
由: Andrea Nizzardo (18316247)
出版: (2025)

Association of a COVID-19 diagnosis with adverse events, SCRI design, marketscan and medicare, follow-up starting on the day after time 0.
由: Shelby S. Fisher (22676406)
出版: (2025)

Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
由: Seyed Reza Mousavi (13223324)
出版: (2025)

Supplementary Figure S1 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
由: Arathi Mohan (15561346)
出版: (2025)

Supplementary Table S4 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
由: Arathi Mohan (15561346)
出版: (2025)

Safety assessment of EBL in zebrafish larvae identifies a non-adverse exposure.
由: Zhuangbin Zheng (22676304)
出版: (2025)

Time-to-onset analysis using the Weibull distribution test.
由: Jun Hua Lai (22676523)
出版: (2025)

Signal strength of ADE at the drug level ranked by reports.
由: Jun Hua Lai (22676523)
出版: (2025)

Characteristics of AEs reports.
由: Jun Hua Lai (22676523)
出版: (2025)

The principles of disproportionate measurement and the criteria for signal detection.
由: Jun Hua Lai (22676523)
出版: (2025)

Gender Difference analysis of the top 50 drugs ranked by frequency by four methods (ROR PRR IC MGPS).
由: Jun Hua Lai (22676523)
出版: (2025)

Outcomes distribution of drug patients with the top 50 positive signal frequency by 4 methods (ROR PRR IC MGPS).
由: Jun Hua Lai (22676523)
出版: (2025)

Top 50 drugs sorted by frequency of positive signals stratified by reporter – by 4 methods (ROR PRR IC MGPS).
由: Jun Hua Lai (22676523)
出版: (2025)

The top 25 drugs sorted by frequency of positive signals stratified by age – by 4 methods (ROR PRR IC MGPS).
由: Jun Hua Lai (22676523)
出版: (2025)

The top 50 drugs by frequency of positive signals stratified by sex – by 4 methods (ROR PRR IC MGPS).
由: Jun Hua Lai (22676523)
出版: (2025)

Top 50 Drugs with positive signals by frequency – by four methods (ROR PRR IC MGPS).
由: Jun Hua Lai (22676523)
出版: (2025)

Flowchart.
由: Jun Hua Lai (22676523)
出版: (2025)

Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
由: Nicola S. Meagher (15048462)
出版: (2025)

Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
由: Nicola S. Meagher (15048462)
出版: (2025)

Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
由: Nicola S. Meagher (15048462)
出版: (2025)

Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
由: Nicola S. Meagher (15048462)
出版: (2025)

Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
由: Nicola S. Meagher (15048462)
出版: (2025)

Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
由: Nicola S. Meagher (15048462)
出版: (2025)

Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
由: Nicola S. Meagher (15048462)
出版: (2025)

Data Sheet 2_Profile and risk factors of blood donors who experienced adverse reactions: a cross-sectional study on donor hemovigilance data reported to the national network from 2020 to 2022 in China.pdf
由: Junhong Yang (7807046)
出版: (2025)

Data Sheet 1_Profile and risk factors of blood donors who experienced adverse reactions: a cross-sectional study on donor hemovigilance data reported to the national network from 2020 to 2022 in China.zip
由: Junhong Yang (7807046)
出版: (2025)

Event triggering effect.
由: Chengliang Chao (22676651)
出版: (2025)

Evolution of anchor chain tension over time under event-triggered control scheme.
由: Chengliang Chao (22676651)
出版: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
由: Anne-Florence Blandin (15056366)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ct788f98kk519a00adeqdmoqec